Nyxoah's DREAM Pivotal Study Data Presented At The International Surgical Sleep Society 2024 Educational Update; Additional Clinical Data On Patients Suffering From Obstructive Sleep Apnea Demonstrate A Clinically Significant 71% Median Reduction In Apnea-Hypopnea Index While Sleeping Supine
Portfolio Pulse from Benzinga Newsdesk
Nyxoah presented data from its DREAM pivotal study at the International Surgical Sleep Society 2024, showing a 71% median reduction in Apnea-Hypopnea Index for patients with Obstructive Sleep Apnea. The study also reported significant improvements in quality-of-life outcomes.
September 27, 2024 | 8:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nyxoah's DREAM study data shows a 71% reduction in Apnea-Hypopnea Index for OSA patients, indicating strong clinical efficacy of their Genio system. This could positively impact Nyxoah's stock price.
The significant reduction in Apnea-Hypopnea Index and improvements in quality-of-life outcomes suggest strong clinical efficacy of Nyxoah's Genio system. This positive data presentation at a major conference could enhance investor confidence and potentially lead to a short-term increase in Nyxoah's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100